Drug firm Zydus Cadila on Sunday said it has received DCGI approval to initiate Phase III clinical trials of its Covid-19 vaccine ZyCoV-D. The company will now be initiating Phase III clinical trial in around 30,000 volunteers, Zydus Cadila said in a statement. ZyCoV-D was found to be safe, well-tolerated and immunogenic in phase I and II clinical trials, it added.

from India News | Latest News Headlines & Live Updates from India - Times of India https://ift.tt/2Lh3fEs
via i